US3463705A - Enzymic polypeptide degradation - Google Patents
Enzymic polypeptide degradation Download PDFInfo
- Publication number
- US3463705A US3463705A US569069A US3463705DA US3463705A US 3463705 A US3463705 A US 3463705A US 569069 A US569069 A US 569069A US 3463705D A US3463705D A US 3463705DA US 3463705 A US3463705 A US 3463705A
- Authority
- US
- United States
- Prior art keywords
- degradation
- actinoplanes
- antibiotic
- enzymic
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000006731 degradation reaction Methods 0.000 title description 12
- 230000015556 catabolic process Effects 0.000 title description 11
- 108090000765 processed proteins & peptides Proteins 0.000 title description 9
- 102000004196 processed proteins & peptides Human genes 0.000 title description 9
- 229920001184 polypeptide Polymers 0.000 title description 8
- 241000187844 Actinoplanes Species 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 230000003115 biocidal effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 10
- 108010092160 Dactinomycin Proteins 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 244000005700 microbiome Species 0.000 description 8
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 5
- 229960000640 dactinomycin Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 229930183665 actinomycin Natural products 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CSOJYIADHHNGRM-UHFFFAOYSA-N (+-)-6-(4-oxo-thiazolidin-2-yl)-hexanoic acid Natural products OC(=O)CCCCCC1NC(=O)CS1 CSOJYIADHHNGRM-UHFFFAOYSA-N 0.000 description 2
- AUJXLBOHYWTPFV-BLWRDSOESA-N CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 Chemical group CS[C@H]1SC[C@H]2N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C(=O)[C@@H]1N(C)C(=O)[C@@H](C)NC(=O)[C@H](COC(=O)[C@@H](C(C)C)N(C)C2=O)NC(=O)c1cnc2ccccc2n1)NC(=O)c1cnc2ccccc2n1 AUJXLBOHYWTPFV-BLWRDSOESA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010009858 Echinomycin Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 108010066860 Vernamycin B Proteins 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 150000002596 lactones Chemical group 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- AUJXLBOHYWTPFV-UHFFFAOYSA-N quinomycin A Natural products CN1C(=O)C(C)NC(=O)C(NC(=O)C=2N=C3C=CC=CC3=NC=2)COC(=O)C(C(C)C)N(C)C(=O)C2N(C)C(=O)C(C)NC(=O)C(NC(=O)C=3N=C4C=CC=CC4=NC=3)COC(=O)C(C(C)C)N(C)C(=O)C1CSC2SC AUJXLBOHYWTPFV-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009105 vegetative growth Effects 0.000 description 2
- -1 20 grams Chemical compound 0.000 description 1
- SATIISJKSAELDC-ZIOPZPSVSA-N 3-hydroxy-N-[(3R,6S,7R,10S,13S,16S,22R,24R)-24-hydroxy-7,11,13,17,20-pentamethyl-16-[(2S)-3-methylbutan-2-yl]-3-(2-methylpropyl)-2,5,9,12,15,18,21-heptaoxo-10-phenyl-8-oxa-1,4,11,14,17,20-hexazabicyclo[20.3.0]pentacosan-6-yl]pyridine-2-carboxamide Chemical compound CC(C)C[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@@H](N(C)C(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)C(C)C)N(C)C(=O)CN(C)C(=O)[C@H]2C[C@@H](O)CN2C1=O)c1ccccc1 SATIISJKSAELDC-ZIOPZPSVSA-N 0.000 description 1
- YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 description 1
- 241000187843 Actinoplanes missouriensis Species 0.000 description 1
- 241001495438 Actinoplanes philippinensis Species 0.000 description 1
- 241000187840 Actinoplanes utahensis Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100102516 Clonostachys rogersoniana vern gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZZMMEAMWBSORN-UHFFFAOYSA-N Mikamycin B Natural products CCC1NC(=O)C(NC(=O)c2ccccc2O)N(C)OC(=O)C(NC(=O)C3CC(=O)CCN3C(=O)C(Cc4ccc(cc4)N(C)C)N(C)C(=O)C5CCCN5C1=O)c6ccccc6 CZZMMEAMWBSORN-UHFFFAOYSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010079780 Pristinamycin Proteins 0.000 description 1
- RLNUPSVMIYRZSM-UHFFFAOYSA-N Pristinamycin Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)CCN(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O RLNUPSVMIYRZSM-UHFFFAOYSA-N 0.000 description 1
- YGXCETJZBDTKRY-UHFFFAOYSA-N Pristinamycin Component I A Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)N(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-UHFFFAOYSA-N 0.000 description 1
- 108010015795 Streptogramin B Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- XMKLKZFSQXZUQU-UHFFFAOYSA-N neoviridogrisein-II Natural products CC1OC(=O)C(C=2C=CC=CC=2)N(C)C(=O)C(C)NC(=O)C(C(C)C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(CC(C)C)NC(=O)C1NC(=O)C1=NC=CC=C1O XMKLKZFSQXZUQU-UHFFFAOYSA-N 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229960003961 pristinamycin Drugs 0.000 description 1
- YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 description 1
- DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 description 1
- JOOMGSFOCRDAHL-XKCHLWDXSA-N pristinamycin-IIB Natural products CC(C)[C@@H]1OC(=O)[C@H]2CCCN2C(=O)c3coc(CC(=O)C[C@@H](O)C=C(C)C=CCNC(=O)C=C[C@H]1C)n3 JOOMGSFOCRDAHL-XKCHLWDXSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- FEPMHVLSLDOMQC-IYPFLVAKSA-N virginiamycin S1 Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC=CC=2)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O FEPMHVLSLDOMQC-IYPFLVAKSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/827—Actinoplanes
Definitions
- This invention relates to the degradation of heterodetic polypeptides. More particularly, this invention relates to the enzymic degradation of heterodetic polypeptide antibiotics, employing growing cultures of a microorganism of the genus Actinoplanes.
- the method of the present invention may be employed to carry out a partial degradation of polypeptide antibiotics. Specifically, opening of the ester bonds in the lactone ring of such po ypeptl es as, or instance, dactifioin'ydifi'a'nd vern'5fiiy5ii'iB"s"rnay be achieved. Such degradates may then be chemically modified, for instance, by attaching another amino acid residue and rejoining the ring, thus providing an analog of the original antibiotic.
- the present invention thus provides the laboratory worker and researchist with a new and valuable diagnostic and investigative tool not heretofore available in the art.
- a microorganism of the genus Actinoplanes is grown under aerobic conditions in a culture medium containing assirnilable carbon, nitrogen, and minerals.
- a quantity of antibiotic or sample containing antibiotic
- antibiotic such as dactinomycin
- the presence of the antibiotic in the growing culture stimulates the production of an enzyme which, in turn, causes the degradation of the polypeptide antibiotic.
- the degradation so achieved is readily determined by paper ionophoresis and ion exchange chromatographic behavior, as well as by degradation by chemical processes.
- heterodetic polypeptide that is, any poly-peptide containing a lactone ring in its structure.
- heterodetic polypeptides which may be degraded in the process of this invention include, but are not limited thereto, d act m LIIOIHYCIII, cactmomycln, actmomyclnE e ta rt ygm, staphy 9;
- '"Tl'ifi'fiidations take placemd efl'ectively under the conditions satisfactory for the growth of the Actinoplanes; that is, a temperature between about and 50 C., preferably about 20 to 40 C., and a pH between about 6 and 9, preferably between about 6.5 and 8, with agitation and aeration.
- the degradations take place at a temperature of about C. and a pH of about 7.
- the culture medium should contain an assimilable source of carbon such as sucrose, glucose, glycerol or the like, a nitrogen source such as peptone, urea, ammonium sulfate or the like, and several inorganic salts found generally to be effective to promote the growth of microorganisms.
- an assimilable source of carbon such as sucrose, glucose, glycerol or the like
- a nitrogen source such as peptone, urea, ammonium sulfate or the like
- several inorganic salts found generally to be effective to promote the growth of microorganisms.
- Applicant has found the use of the commercially available culture medium designated Staleys Special Nutrient 4-S, employed in combination with glycerol, to be particularly suitable although any standard culture medium known in the art meeting the above requirements may be utilized.
- the Actinoplanes genus microorganism are operable as a group in the process of the present invention.
- species of this genus are Actinoplanes missouriensis (ATCC 14,538), Actinoplanes utahensis (ATCC 14,539), Actinoplanes philippinensis and Actinoplanes species IMRU F3-l5.
- the use of Actinoplanes species IMRU F3-l5 is preferred in the present process.
- Example 1 A culture of Actinoplanes species IMRU F3-15 is grown in a submerged culture in a medium containing 30 grams per liter of Staleys Special Nutrient 4-8 and 20 grams per liter of glycerol. The culture is grown under moderate aeration ml. medium in a 250 ml. Erlenmeyer flask placed on a rotary shaker at 280 r.p.m. and 1 inch displacement) at a temperature between 23 and 37 C. After about four days incubation, 5 ml. of vegetative growth is used to inoculate a series of flasks (100 ml. of medium per each 500 ml.
- This cell suspension containing the enzyme, is used to degrade the antibiotics directly by placing the suspension in aerated beakers, adding dactinomycin to give a concentration of 10 to 1,000 mcg. per ml. and aerating the mixture for 4 to 10 hours. At the end of this period essentially all of the antibacterial activity has disappeared (as measured by bioassay using Staphylococcus aureus 209P).
- the degradation products are recovered by either solvent extraction or ion exchange chromatography, and include dactinomycinic acid and dactinomycin monolactone.
- Actinoplanes species IMRU F3-15 is grown in shaken flasks (100 ml. per 250 ml. Erlenmeyer flask) placed on a rotary shaker r.p.m., 1 inch displacement), located in a room maintained at 2830 C.
- the nutrient medium contained Staleys Special Nutrient 4-8, 30 grams, glycerol, 20 grams, and distilled water q.s. 1 liter.
- the flasks are inoculated with 5% transfer of vegetative growth of a 4- day old culture grown in this medium. After three days incubation, 1 mg. of actinomycin complex is added to one flask and incubation continued for 18 hours.
- the contents of the flasks are then collected by centrifugation and the solids resuspended in 100 ml. of phosphate buffer (0.02 M, pH 7.0). Ten ml. of this suspension is placed in a 50 ml. Erlenmeyer flask and 1 mg. of antibiotic added to the suspension. A zero-time sample is taken and extracted with CHCl, (equal volume). After three hours incubation at 30 C., a second sample is taken (usually 5 ml) 3 and similarly extracted. The antibiotic content of the extracts is determined by bioassay using Staphylococcus aureus 209P (agar diifusion assay). More than 90% of the antibiotic activity of the treated actinomycin has disappeared during the incubation.
- Example 3 The process of Example 2 is followed except that vernamycin B is substituted for the actinomycin complex. In this case, also, antibiotic activity decreases by over 90%.
- Example 4 Following the procedure of Example 2, but substituting echinomycin for the actinomycin complex, substantially the same result is achieved. The antibiotic activity is diminished by over 90% during the incubation.
- Example 5 mycin, acitnomycin, etamycin, staphylomycin S, pristinamycin I, mikamycin B, vernamycin B, and echinomycin which comprises exposing said polypeptide to the action of a microorganism of the genus Actinoplanes for a time sufficient to achieve substantially degradation of said polypeptide.
- a process in accordance with claim 1 wherein the microorganism is Actinoplanes species IMRU F3-15.
- heterodetic polypeptide is dactinomycin and the microorganism is Actinoplanes species IMRU F3-15.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
QUE J1. F
xii. lie-46311785 Patented Aug. 26, 1969 3,463,705 ENZYMIC POLYPEPTlDE DEGRADATION David Perlman, Princeton, N.J., assignor to E. R. Squibb 8: Sons, Inc., New York, N.Y., a corporation of Delaware N Drawing. Filed Aug. 1, 1966, Ser. No. 569,069 Int. Cl. Cl2d 13/06; C12k 1/00 U.S. Cl. 195-80 4 Claims ABSTRACT OF THE DISCLOSURE Disclosed herein is a process for degrading heterodetic polypeptides by utilizing microorganisms of the genus Actinoplanes.
This invention relates to the degradation of heterodetic polypeptides. More particularly, this invention relates to the enzymic degradation of heterodetic polypeptide antibiotics, employing growing cultures of a microorganism of the genus Actinoplanes.
During the course of antibiotic treatment, it is often desirable to eliminate any antibiotic activity present in blood and other body fluid samples in order that hitherto unsuspected bacteria can be detected or that further biochemical tests can be performed.
Such inactivation previously required comparatively drastic treatment, such as acid hydrolysis, in order to achieve the desired degree of antibiotic degradation, whereas, by the present invention, a method is provided whereby such antibiotics can be safely and thoroughly removed from blood or other body fluid samples without the necessity of subjecting said samples to the drastic conditions heretofore required.
Further, the method of the present invention may be employed to carry out a partial degradation of polypeptide antibiotics. Specifically, opening of the ester bonds in the lactone ring of such po ypeptl es as, or instance, dactifioin'ydifi'a'nd vern'5fiiy5ii'iB"s"rnay be achieved. Such degradates may then be chemically modified, for instance, by attaching another amino acid residue and rejoining the ring, thus providing an analog of the original antibiotic. The present invention thus provides the laboratory worker and researchist with a new and valuable diagnostic and investigative tool not heretofore available in the art.
In one embodiment of the invention, a microorganism of the genus Actinoplanes is grown under aerobic conditions in a culture medium containing assirnilable carbon, nitrogen, and minerals. To the culture thus obtained is added a quantity of antibiotic (or sample containing antibiotic), such as dactinomycin, and the incubation is continued. The presence of the antibiotic in the growing culture stimulates the production of an enzyme which, in turn, causes the degradation of the polypeptide antibiotic. The degradation so achieved is readily determined by paper ionophoresis and ion exchange chromatographic behavior, as well as by degradation by chemical processes.
The above degradation processes is generally applicable to heterodetic polypeptide (that is, any poly-peptide containing a lactone ring in its structure). Examples of heterodetic polypeptides which may be degraded in the process of this invention include, but are not limited thereto, d act m LIIOIHYCIII, cactmomycln, actmomyclnE e ta rt ygm, staphy 9;
mycin' Sfpris ycln I, m1 yein vernarlnyg in B and EEEiiEmfii'n'Tand the related trio s iii com lex).
'"Tl'ifi'fiidations take placemd efl'ectively under the conditions satisfactory for the growth of the Actinoplanes; that is, a temperature between about and 50 C., preferably about 20 to 40 C., and a pH between about 6 and 9, preferably between about 6.5 and 8, with agitation and aeration. Optimally, the degradations take place at a temperature of about C. and a pH of about 7. The culture medium should contain an assimilable source of carbon such as sucrose, glucose, glycerol or the like, a nitrogen source such as peptone, urea, ammonium sulfate or the like, and several inorganic salts found generally to be effective to promote the growth of microorganisms. Applicant has found the use of the commercially available culture medium designated Staleys Special Nutrient 4-S, employed in combination with glycerol, to be particularly suitable although any standard culture medium known in the art meeting the above requirements may be utilized.
The Actinoplanes genus microorganism are operable as a group in the process of the present invention. Examples of species of this genus are Actinoplanes missouriensis (ATCC 14,538), Actinoplanes utahensis (ATCC 14,539), Actinoplanes philippinensis and Actinoplanes species IMRU F3-l5. The use of Actinoplanes species IMRU F3-l5 is preferred in the present process.
The invention will be more clearly understood from the following operating examples, which are intended to be illustrative only, and not as limitations on the scope of the invention.
Example 1 A culture of Actinoplanes species IMRU F3-15 is grown in a submerged culture in a medium containing 30 grams per liter of Staleys Special Nutrient 4-8 and 20 grams per liter of glycerol. The culture is grown under moderate aeration ml. medium in a 250 ml. Erlenmeyer flask placed on a rotary shaker at 280 r.p.m. and 1 inch displacement) at a temperature between 23 and 37 C. After about four days incubation, 5 ml. of vegetative growth is used to inoculate a series of flasks (100 ml. of medium per each 500 ml. Erlenmeyer flask) and the second series of flasks are placed on the shaker. After about three days incubation, 0.2 ml. of a 50% aqueous ethanol solution containing 5 mg. of dactinomycin per ml. are added to each flask and the fermentation continued for 12 to 18 hours. At the end of the incubation period, the contents of the flasks are collected by centrifugation and resuspended in 0.1 to 0.2 M phosphate buffer (pH 7.0). The solids are again collected by centrifugation and resuspended in the phosphate buffer. This cell suspension, containing the enzyme, is used to degrade the antibiotics directly by placing the suspension in aerated beakers, adding dactinomycin to give a concentration of 10 to 1,000 mcg. per ml. and aerating the mixture for 4 to 10 hours. At the end of this period essentially all of the antibacterial activity has disappeared (as measured by bioassay using Staphylococcus aureus 209P). The degradation products are recovered by either solvent extraction or ion exchange chromatography, and include dactinomycinic acid and dactinomycin monolactone.
Example 2 Actinoplanes species IMRU F3-15 is grown in shaken flasks (100 ml. per 250 ml. Erlenmeyer flask) placed on a rotary shaker r.p.m., 1 inch displacement), located in a room maintained at 2830 C. The nutrient medium contained Staleys Special Nutrient 4-8, 30 grams, glycerol, 20 grams, and distilled water q.s. 1 liter. The flasks are inoculated with 5% transfer of vegetative growth of a 4- day old culture grown in this medium. After three days incubation, 1 mg. of actinomycin complex is added to one flask and incubation continued for 18 hours. The contents of the flasks are then collected by centrifugation and the solids resuspended in 100 ml. of phosphate buffer (0.02 M, pH 7.0). Ten ml. of this suspension is placed in a 50 ml. Erlenmeyer flask and 1 mg. of antibiotic added to the suspension. A zero-time sample is taken and extracted with CHCl, (equal volume). After three hours incubation at 30 C., a second sample is taken (usually 5 ml) 3 and similarly extracted. The antibiotic content of the extracts is determined by bioassay using Staphylococcus aureus 209P (agar diifusion assay). More than 90% of the antibiotic activity of the treated actinomycin has disappeared during the incubation.
Example 3 The process of Example 2 is followed except that vernamycin B is substituted for the actinomycin complex. In this case, also, antibiotic activity decreases by over 90%.
Example 4 Following the procedure of Example 2, but substituting echinomycin for the actinomycin complex, substantially the same result is achieved. The antibiotic activity is diminished by over 90% during the incubation.
Example 5 mycin, acitnomycin, etamycin, staphylomycin S, pristinamycin I, mikamycin B, vernamycin B, and echinomycin which comprises exposing said polypeptide to the action of a microorganism of the genus Actinoplanes for a time sufficient to achieve substantially degradation of said polypeptide.
2. A process in accordance with claim 1 wherein said exposure takes place at a temperature between about 20 and C. and at a pH between about 6 and 9.
3. A process in accordance with claim 1 wherein the microorganism is Actinoplanes species IMRU F3-15.
4. A process in accordance with claim 1 wherein the heterodetic polypeptide is dactinomycin and the microorganism is Actinoplanes species IMRU F3-15.
References Cited Katz et al., Science, vol. 126, 1957, pp. 402-403, copy in Scientific Library.
MAURICE W. GREENSTEIN, Primary Examiner US. Cl. X.R.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56906966A | 1966-08-01 | 1966-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3463705A true US3463705A (en) | 1969-08-26 |
Family
ID=24273974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US569069A Expired - Lifetime US3463705A (en) | 1966-08-01 | 1966-08-01 | Enzymic polypeptide degradation |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3463705A (en) |
-
1966
- 1966-08-01 US US569069A patent/US3463705A/en not_active Expired - Lifetime
Non-Patent Citations (1)
| Title |
|---|
| None * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US2739924A (en) | Production of tetracycline | |
| DE3018767A1 (en) | METHOD FOR PRODUCING ISOPENICILLIN N USING A CELL-FREE MUSHROOM CULTURE EXTRACT | |
| US2422230A (en) | Production of streptothricin | |
| US3463705A (en) | Enzymic polypeptide degradation | |
| EP0082114A1 (en) | Microorganisms of the genus Hyphomicrobium and method for the decomposition of compounds containing methyl groups in aqueous solutions | |
| US3592925A (en) | Antibiotics ah272alpha2 and ah272beta2 and process for producing same | |
| De Waart et al. | Lysogenic conversion in staphylococci | |
| SU575038A3 (en) | Method of preparing antibiotic | |
| EP0073329A1 (en) | Process for producing the antibiotic nosiheptide | |
| US3756916A (en) | Tants obtained therefrom method of isolating amino acid producing mutant microorganisms and mu | |
| Lowe et al. | Ecological studies on coccoid bacteria in a pine forest soil—II. Growth of bacteria introduced into soil | |
| SU507204A3 (en) | The method of obtaining (+) salyutaridina | |
| US2840578A (en) | 9alpha-hydroxyprogesterone | |
| US2880217A (en) | delta1, 4 pregnadiene-11alpha, 20beta-diol-3-one | |
| US3125495A (en) | Microbial preparation of | |
| US3663373A (en) | Process for the preparation of iodinin | |
| US3222257A (en) | Process for producing nucleosides by microorganisms | |
| US3901880A (en) | (s)-alanyl-3-(+60 -(s)-chloro-3-(s)-hydroxy-2-oxo-azetidinylmethyl)-(s)-alanine | |
| US3119749A (en) | Process for preparing 1-dehydro steroids | |
| SU494382A1 (en) | Method for preparing hydrocortisone and cortisone acetate | |
| US4430431A (en) | Producing fusafungine | |
| US2868694A (en) | Synthesis of 1, 2-dehydro steroid by cylindrocarpon radicicola or fusarium javanicum | |
| US2770574A (en) | Selective enrichment medium for salmonella | |
| DE1568025A1 (en) | Process for the production of equilin | |
| US3733254A (en) | Method of preparing d-13beta-ethylgona-1,3,5(10)-triene-2,16alpha,17beta-triol |